Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could a blood gel patch up anal fistulas without surgery?

NCT ID NCT05641844

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new treatment called RD2 Ver.02, a gel made from a patient's own blood, for healing anal fistulas. About 110 adults with certain types of fistulas will receive either the gel or a saltwater placebo after the fistula is cleaned and stitched closed. The main goal is to see if the gel helps the fistula heal better and with fewer complications over 6 months, and if it stays healed after a year.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
RD2 Ver.02 (a gel made from the patient's own blood)
What this could lead to
If it works, this could offer a simple, non-surgical way to heal anal fistulas and reduce the chance of them coming back.
What could go wrong
This is an early-stage trial with only 110 people, so results may not apply to everyone. The treatment might not heal the fistula or could cause infection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 110 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2024

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Subject is ≥18 years of age * Subject has a transsphincteric or long intersphincteric anal fistula (\>1.5 cm), with a seton in place for a minimum of 1 month, deemed eligible for primary or repeat fistula repair by anorectal advancement flap or LIFT: Anterior, posterior or lateral fistula, first or recurrent, at any position circumferentially, with one external opening and one internal opening. * Subjects is unable or unwilling to receive invasive surgical procedures, anorectal advancement flap or LIFT procedure, and is opting for minimally invasive technique of anal fistula management (i.e., fistula tract debridement and suturing of internal opening). * 2.1.4 Prior to enrollment, during the preceding 3 months from Treatment Visit, subject must undergo a pelvic MRI to evaluate eligibility criteria unable to be assessed clinically. * Female subjects who are capable of conceiving and all males capable of insemination must use an acceptable form of contraception in order to participate in the study and for 6 months following study procedure (acceptable forms of contraception include condoms for males and contraceptive pills or IUDs for women) Exclusion Criteria: * Subject who has a life expectancy of less than 24 months. * Subjects who are cognitively impaired and have a healthcare proxy or those who are cognitively impaired and clearly do not understand the contents of the informed consent form. * Cannot withdraw blood in the required amount (up to 15 mL). * Women who are pregnant or currently breast feeding. * Subject is currently receiving (i.e., within the past 30 days) or scheduled to receive systemic steroids (more than 10mg per day). * Multiple fistula tracts, as confirmed on pelvic MRI * Short fistula tract that in the surgeon's opinion are amenable to fistulotomy * Active infection including perianal infection, and/or any active systemic or local infection. * Presence of a perirectal abscess on pelvic MRI * Presence of dominant luminal active Crohn's disease, validated by recent colonoscopy from preceding 12 months, requiring immediate therapy * Rectal and/or anal stenosis and / or active proctitis, if this means a limitation for any surgical procedure. * Known allergies or hypersensitivity to any of the following: antibiotics including but not limited to penicillin, streptomycin, gentamicin, aminoglycosides; Human Serum Albumin (HSA); Dulbecco Modified Eagle's Medium (DMEM); materials of bovine origin; local anaesthetics or gadolinium (MRI contrast); Known hypersensitivity to reagents and components of RD2 Ver.02 including calcium gluconate, Kaolin or citrate and ethylene oxide. * Contraindication to MRI scan, (e.g., due to the presence of pacemakers, hip replacements, or severe claustrophobia). * Known coagulation problems, abnormal thrombocytes level or if heparin is given intravenously. Subjects who are taking Coumadin, Aspirin, Plavix (Clopidogrel), Eliquis or Pradaxa will not be excluded. * Patients with increased risk for the surgical procedure or major alteration of any of the following laboratory tests: 1. Serum Creatinine levels \>1.5 times the upper limit of normality (ULN) 2. Total bilirubin \>1.5 times the ULN (unless predominantly non conjugated due to documented history of Gilbert's syndrome) 3. AST/ ALT \>3.0 times the ULN 4. Hemoglobin \<10.0 g/dL 5. Platelets \<150.0 x109/L 6. Albuminemia \<3.0 g/dL. * Patients who do not wish to or cannot comply with study procedures. * Patients currently receiving or having received within 12 months prior to enrolment into this clinical study, any investigational drug. * Subjects who need surgery in the perianal region for reasons other than fistulas at the time of inclusion in the study, or for whom such surgery is foreseen in this region in the 24 weeks after treatment administration. * Contraindication to the anesthetic procedure. * Subject with a diagnosis of Ulcerative Colitis * Subject with malignancy, undergoing active treatment * Rectovaginal fistula * History of pelvic radiation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anal fistula are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    9 sites in 2 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Allegheny Health Network

    RECRUITING

    Pittsburgh, Pennsylvania, 15212, United States

  • Brown surgical associates

    RECRUITING

    Providence, Rhode Island, 02904, United States

  • Cleveland Clinic

    RECRUITING

    Weston, Florida, 33331, United States

  • Franciscan Health

    RECRUITING

    Indianapolis, Indiana, 46237, United States

  • Karen Zaghiyan, M.D

    COMPLETED

    Los Angeles, California, 90048, United States

  • Lenox Hill Hospital

    RECRUITING

    New York, New York, 10075, United States

  • Mayo Clinic

    RECRUITING

    Rochester, Minnesota, 55905, United States

  • Sheba Medical Center

    RECRUITING

    Ramat Gan, Israel

  • UMASS

    RECRUITING

    Worcester, Massachusetts, 01605, United States

  • University of Chicago

    RECRUITING

    Chicago, Illinois, 60637, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.